| Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients A Zehir, R Benayed, RH Shah, A Syed, S Middha, HR Kim, P Srinivasan, ... Nature medicine 23 (6), 703-713, 2017 | 3235 | 2017 |
| HER kinase inhibition in patients with HER2-and HER3-mutant cancers DM Hyman, SA Piha-Paul, H Won, J Rodon, C Saura, GI Shapiro, D Juric, ... Nature 554 (7691), 189-194, 2018 | 758 | 2018 |
| Genome doubling shapes the evolution and prognosis of advanced cancers CM Bielski, A Zehir, AV Penson, MTA Donoghue, W Chatila, J Armenia, ... Nature genetics 50 (8), 1189-1195, 2018 | 573 | 2018 |
| How I treat hemophagocytic lymphohistiocytosis in the adult patient AM Schram, N Berliner Blood, The Journal of the American Society of Hematology 125 (19), 2908-2914, 2015 | 437 | 2015 |
| A next-generation TRK kinase inhibitor overcomes acquired resistance to prior TRK kinase inhibition in patients with TRK fusion–positive solid tumors A Drilon, R Nagasubramanian, JF Blake, N Ku, BB Tuch, K Ebata, S Smith, ... Cancer discovery 7 (9), 963-972, 2017 | 416 | 2017 |
| A germline JAK2 SNP is associated with predisposition to the development of JAK2V617F-positive myeloproliferative neoplasms O Kilpivaara, S Mukherjee, AM Schram, M Wadleigh, A Mullally, BL Ebert, ... Nature genetics 41 (4), 455-459, 2009 | 413 | 2009 |
| High yield of RNA sequencing for targetable kinase fusions in lung adenocarcinomas with no mitogenic driver alteration detected by DNA sequencing and low tumor mutation burden R Benayed, M Offin, K Mullaney, P Sukhadia, K Rios, P Desmeules, ... Clinical Cancer Research 25 (15), 4712-4722, 2019 | 398 | 2019 |
| Accelerating discovery of functional mutant alleles in cancer MT Chang, TS Bhattarai, AM Schram, CM Bielski, MTA Donoghue, ... Cancer discovery 8 (2), 174-183, 2018 | 352 | 2018 |
| Fusions in solid tumours: diagnostic strategies, targeted therapy, and acquired resistance AM Schram, MT Chang, P Jonsson, A Drilon Nature reviews Clinical oncology 14 (12), 735-748, 2017 | 306 | 2017 |
| Marked hyperferritinemia does not predict for HLH in the adult population AM Schram, F Campigotto, A Mullally, A Fogerty, E Massarotti, D Neuberg, ... Blood, The Journal of the American Society of Hematology 125 (10), 1548-1552, 2015 | 250 | 2015 |
| Resistance to TRK inhibition mediated by convergent MAPK pathway activation E Cocco, AM Schram, A Kulick, S Misale, HH Won, R Yaeger, P Razavi, ... Nature medicine 25 (9), 1422-1427, 2019 | 201 | 2019 |
| COVID-19 vaccine guidance for patients with cancer participating in oncology clinical trials A Desai, JF Gainor, A Hegde, AM Schram, G Curigliano, S Pal, SV Liu, ... Nature reviews Clinical oncology 18 (5), 313-319, 2021 | 165 | 2021 |
| Haemophagocytic lymphohistiocytosis in adults: a multicentre case series over 7 years AM Schram, P Comstock, M Campo, D Gorovets, A Mullally, K Bodio, ... British Journal of Haematology 172 (3), 412-419, 2016 | 162 | 2016 |
| Colorectal carcinomas containing hypermethylated MLH1 promoter and wild-type BRAF/KRAS are enriched for targetable kinase fusions E Cocco, J Benhamida, S Middha, A Zehir, K Mullaney, J Shia, R Yaeger, ... Cancer research 79 (6), 1047-1053, 2019 | 158 | 2019 |
| TRK fusions are enriched in cancers with uncommon histologies and the absence of canonical driver mutations EY Rosen, DA Goldman, JF Hechtman, R Benayed, AM Schram, E Cocco, ... Clinical Cancer Research 26 (7), 1624-1632, 2020 | 150 | 2020 |
| Efficacy and Determinants of Response to HER Kinase Inhibition in HER2-Mutant Metastatic Breast Cancer LM Smyth, SA Piha-Paul, HH Won, AM Schram, C Saura, S Loi, J Lu, ... Cancer discovery 10 (2), 198-213, 2020 | 119 | 2020 |
| Zenocutuzumab, a HER2xHER3 Bispecific Antibody, Is Effective Therapy for Tumors Driven by NRG1 Gene Rearrangements AM Schram, I Odintsov, M Espinosa-Cotton, I Khodos, WJ Sisso, ... Cancer Discovery 12 (5), 1233-1247, 2022 | 118 | 2022 |
| Widespread selection for oncogenic mutant allele imbalance in cancer CM Bielski, MTA Donoghue, M Gadiya, AJ Hanrahan, HH Won, ... Cancer cell 34 (5), 852-862. e4, 2018 | 106 | 2018 |
| A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours AM Schram, L Gandhi, MM Mita, L Damstrup, F Campana, M Hidalgo, ... British journal of cancer 119 (12), 1471-1476, 2018 | 91 | 2018 |
| Basket studies: redefining clinical trials in the era of genome-driven oncology JJ Tao, AM Schram, DM Hyman Annual review of medicine 69 (1), 319-331, 2018 | 82 | 2018 |
